All In Biotech

Drug Trial Radar · NCT02318277

A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

Last checked: Nov 19, 2026Latest source record: Jan 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

176

Actual

Start

Jan 5, 2015

Primary completion

Aug 28, 2019

Study completion Oct 16, 2020

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
Collaborators
AstraZeneca
First posted
Dec 17, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to explore the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of INCB024360 administered in combination with MEDI4736 in subjects with selected advanced solid tumors.

Conditions

  • Solid Tumors
  • Head and Neck Cancer
  • Lung Cancer
  • UC (Urothelial Cancer)

Interventions

  • MEDI4736Drug

    MEDI4736 administered intravenously (IV) every two weeks (q2w)

  • INCB024360Drug

    INCB024360: Oral daily dosing

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 : Number of Treatment-Emergent Adverse Events (TEAE)Time frame: Duration of study treatment and up to 90 days after the last dose [approximately 3 years]
  2. Phase 2: Objective Response Rate (ORR) as Determined by Radiographic Disease Assessments Per Modified Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: Measured every 8 weeks for duration of study treatment [approximately 12 months]

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    San Francisco, California

  • Site not named

    Denver, Colorado

  • Site not named

    Miami, Florida

  • Site not named

    Port Saint Lucie, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Chicago, Illinois

  • Site not named

    Louisville, Kentucky

  • Site not named

    Durham, North Carolina

  • Site not named

    Huntersville, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Dallas, Texas

  • Site not named

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.